Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wayfair Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.53 (market cap $772.39M), while Wayfair Inc trades at $105.75 (market cap $14.31B). The key difference: Wayfair Inc is far larger — about 18.5× Ginkgo Bioworks Holdings Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Wayfair Inc for 8 Days on average.
| DNA | W | |
|---|---|---|
Market Cap | $772.39M | $14.31B |
Volume | 6,453,273 | 1,595,934 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $119.05 |
52-Week Low | $5.48 | $57.40 |
Typical Hold Time | 7 Days | 8 Days |
Enterprise Value | $874.34M | $16.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Wayfair (W) trades at $104.47, down 0.93% with a bullish technical outlook. The company shows mixed fundamentals with $12.46B revenue but negative net margins, while analysts maintain a buy consensus with a $114.06 price target. Recent developments include store expansion and upcoming Q3 earnings.
The stock presents upside potential from analyst targets and operational cash flow growth, but faces risks from persistent losses and high debt. Key catalysts include Q3 earnings on November 4, 2026, and execution of the new brand platform amid competitive retail pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
